<DOC>
	<DOCNO>NCT01556022</DOCNO>
	<brief_summary>This prospective , randomize , placebo-controlled , double blind safety feasibility clinical trial .</brief_summary>
	<brief_title>Safety Feasibility Trial Adipose-Derived Regenerative Cells Treatment Chronic Myocardial Ischemia</brief_title>
	<detailed_description>To assess safety feasibility Adipose-Derived Regenerative Cells ( ADRCs ) deliver via intramyocardial route treatment chronic ischemic heart disease patient eligible percutaneous surgical revascularization .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<criteria>Key 1 . Males females 2080 year age 2 . Significant multivessel coronary artery disease amenable percutaneous surgical revascularization target area 3 . CCS Angina Functional Class IIIV and/or NYHA Stages Heart Failure Class II III 4 . On maximal medical therapy anginal symptom heart failure symptoms 5 . Hemodynamic stability ( Systolic Blood Pressure ≥ 90 mm/Hg , Heart Rate &lt; 110 ; PulseOxygen &gt; 95 ) 6 . Ejection fraction ≤ 45 7 . Left ventricular wall thickness ≥ 8 mm target site cell injection , confirm 2D contrast echo within 4 week prior enrollment , free thrombus Key 1 . Atrial fibrillation flutter without pace maker guarantee stable heart rate 2 . Unstable angina 3 . LV thrombus , document echocardiography 4 . Planned stag treatment CAD intervention heart 5 . Platelet count &lt; 100,000/mm3 6 . WBC &lt; 2,000/mm3 7 . TIA stroke within 90 day prior randomization 8 . ICD shock within 30 day randomization 9 . Any condition require immunosuppressive medication 10 . A highrisk acute coronary syndrome ( ACS ) myocardial infarction within 60 day prior randomization 11 . Revascularization within 60 day prior randomization 12 . Inability walk treadmill except class IV angina patient evaluate separately 13 . Hepatic dysfunction , define aspartate aminotransferase ( AST ) /or alanine aminotransferase ( ALT ) &gt; 1.5 time upper limit normal range ( x ULN ) prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Ischemic heart disease</keyword>
	<keyword>Coronary artery disease</keyword>
	<keyword>Chronic heart failure</keyword>
	<keyword>Cardiovascular disease</keyword>
	<keyword>Adult stem cell</keyword>
	<keyword>Adipose derive regenerative cell</keyword>
</DOC>